ArticlePloS one2012
A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Rotavirus vaccine coverage, completion, and compliance: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean.BMC pediatrics · 2017Pooled it
- Systematic review of the economic value of diarrheal vaccines.Human vaccines & immunotherapeutics · 2014Pooled it
- Long-term Rotarix Vaccine Effectiveness in Coastal Kenya, Estimated From Child Hospital Admissions Data From July 2014 to December 2022.Open forum infectious diseases · 2026Article
- Supply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review.PLOS global public health · 2026Article
- Diverse processes in rotavirus vaccine development.Human vaccines & immunotherapeutics · 2025Review
- Article
- Improving the Suitability of Vaccine Design for Immunisation Programmes and Enhancing Vaccine Policy Quality Through User Research.Vaccines · 2025Article
- Cost-effectiveness analysis measuring the total costs against the health benefits of three different rotavirus vaccines for Mexico.Human vaccines & immunotherapeutics · 2023Article
- A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Rotavirus vaccine implementation: evidence to fill the gap?The Lancet. Global health · 2021Article
- Effect of childhood rotavirus vaccination on community rotavirus prevalence in rural Ecuador, 2008-13.International journal of epidemiology · 2020Article
- Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.The Lancet. Global health · 2019Article
- Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya.Vaccine · 2019Article
- Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.Vaccine · 2018Article
- Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.Human vaccines & immunotherapeutics · 2018Article
- Cohort Profile: The Kilifi Vaccine Monitoring Study.International journal of epidemiology · 2017Article
- Current state and challenges in developing oral vaccines.Advanced drug delivery reviews · 2017Review
- Article
- Variation in rotavirus vaccine coverage by sub-counties in Kenya.Tropical medicine and health · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDiarrhoea is an important cause of death in the developing world, and rotavirus is the single most important cause of diarrhoea associated mortality. Two vaccines (Rotarix and RotaTeq) are available to prevent rotavirus disease. This analysis was undertaken to aid the decision in Kenya as to which vaccine to choose when introducing rotavirus vaccination.
methodsCost-effectiveness modelling, using national and sentinel surveillance data, and an impact assessment on the cold chain.
resultsThe median estimated incidence of rotavirus disease in Kenya was 3015 outpatient visits, 279 hospitalisations and 65 deaths per 100,000 children under five years of age per year. Cumulated over the first five years of life vaccination was predicted to prevent 34% of the outpatient visits, 31% of the hospitalizations and 42% of the deaths. The estimated prevented costs accumulated over five years totalled US$1,782,761 (direct and indirect costs) with an associated 48,585 DALYs. From a societal perspective Rotarix had a cost-effectiveness ratio of US$142 per DALY (US$5 for the full course of two doses) and RotaTeq US$288 per DALY ($10.5 for the full course of three doses). RotaTeq will have a bigger impact on the cold chain compared to Rotarix.
conclusionVaccination against rotavirus disease is cost-effective for Kenya irrespective of the vaccine. Of the two vaccines Rotarix was the preferred choice due to a better cost-effectiveness ratio, the presence of a vaccine vial monitor, the requirement of fewer doses and less storage space, and proven thermo-stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.